Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of cediranib (Recentin) for symptomatic malignant ascites or pleural effusion
2010-018275-20Phase 2Active
- Sponsor
- Radboud University Medical Center
- Start
- Jan 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in malignant ascites and pleural effusion, sponsored by Radboud University Medical Center. Started Jan 2010; status: active.
02
Drugs
bevacizumab
03
Conditions
malignant ascitespleural effusion
Beyond the preview
Go deeper on 2010-018275-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018275-20.